scholarly journals Early Detection of Hearing Impairment in Neonates - Screening by Otoacoustic Emission Test

2021 ◽  
Vol 8 (07) ◽  
pp. 384-390
Author(s):  
Venkat Nagender Reddy Karkala ◽  
Mounika Thopicharla ◽  
Jyothi Ramakrishna ◽  
Rama Krishna Tirumala Bukkapatnam
Keyword(s):  
Hearing Loss ◽  
High Risk ◽  
Early Detection ◽  
Hearing Impairment ◽  
Otoacoustic Emissions ◽  
Risk Group ◽  
Otoacoustic Emission ◽  
High Risk Group ◽  
Speech Development ◽  
Two Stage

BACKGROUND Approximately 3 per 1000 live births suffer from congenital hearing loss in India. If detected before the age of 6 months, their mental, social and intellectual growth can be restored by early intervention and rehabilitation. Their speech development and social integration depends highly on early detection of hearing loss, at least before the first birthday. We wanted to screen all new-borns for hearing and assess the incidence of hearing impairment in at risk and no risk cases by using otoacoustic emissions. We also wanted to evaluate the two-stage testing by OAE in screening programme. METHODS The present study was conducted from Feb. 1st 2013 to Jan. 31st 2015. A total of 849 infants have been studied of which 63 had high risk factors. RESULTS The overall incidence of hearing impairment was found to be 3.75 / 1000 births in no-risk group whereas 61.22 / 1000 were found in high risk group. CONCLUSIONS Early detection of hearing loss in infants by otoacoustic emission (OAE) is a reliable tool. It conforms with high precision when done with a two-stage protocol that reduces false apprehensions. KEYWORDS Neonatal Hearing Loss, Universal Screening, Otoacoustic Emissions, Brain Stem Evoked Response Audiometry (BSERA), OAE

scholarly journals New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES Trial): protocol of a prospective, multicentre observational trial

BMJ Open ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. e037267
Author(s):  
Dóra Illés ◽  
Emese Ivány ◽  
Gábor Holzinger ◽  
Klára Kosár ◽  
M Gordian Adam ◽  
...  
Keyword(s):  
High Risk ◽  
Early Detection ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Clinical Symptoms ◽  
Risk Group ◽  
High Risk Group ◽  
Ductal Adenocarcinoma ◽  
Onset Diabetes ◽  
Dismal Prognosis ◽  
New Onset

IntroductionPancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with an overall 5-year survival of approximately 8%. The success in reducing the mortality rate of PDAC is related to the discovery of new therapeutic agents, and to a significant extent to the development of early detection and prevention programmes. Patients with new-onset diabetes mellitus (DM) represent a high-risk group for PDAC as they have an eightfold higher risk of PDAC than the general population. The proposed screening programme may allow the detection of PDAC in the early, operable stage. Diagnosing more patients in the curable stage might decrease the morbidity and mortality rates of PDAC and additionally reduce the burden of the healthcare.Methods and analysisThis is a prospective, multicentre observational cohort study. Patients ≥60 years old diagnosed with new-onset (≤6 months) diabetes will be included. Exclusion criteria are (1) Continuous alcohol abuse; (2) Chronic pancreatitis; (3) Previous pancreas operation/pancreatectomy; (4) Pregnancy; (5) Present malignant disease and (6) Type 1 DM. Follow-up visits are scheduled every 6 months for up to 36 months. Data collection is based on questionnaires. Clinical symptoms, body weight and fasting blood will be collected at each, carbohydrate antigen 19–9 and blood to biobank at every second visit. The blood samples will be processed to plasma and analysed with mass spectrometry (MS)-based metabolomics. The metabolomic data will be used for biomarker validation for early detection of PDAC in the high-risk group patients with new-onset diabetes. Patients with worrisome features will undergo MRI or endoscopic ultrasound investigation, and surgical referral depending on the radiological findings. One of the secondary end points is the incidence of PDAC in patients with newly diagnosed DM.Ethics and disseminationThe study has been approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (41085-6/2019). We plan to disseminate the results to several members of the healthcare system includining medical doctors, dietitians, nurses, patients and so on. We plan to publish the results in a peer-reviewed high-quality journal for professionals. In addition, we also plan to publish it for lay readers in order to maximalise the dissemination and benefits of this trial.Trial registration numberClinicalTrials.gov NCT04164602

scholarly journals Η συμβολή των ωτοακουστικών εκπομπών στη μελέτη της κοχλιακής λειτουργίας σε ασθενείς με υποθυρεοειδισμό

2013 ◽  
Author(s):  
Βασίλειος Ψαλτάκος
Keyword(s):  
Hearing Loss ◽  
Hearing Impairment ◽  
Otoacoustic Emissions ◽  
Pure Tone ◽  
Pure Tone Audiometry ◽  
Otoacoustic Emission ◽  
Upper Respiratory Tract ◽  
Anatomic Site ◽  
Cochlear Function ◽  
Hearing Thresholds

Although several reports exist concerning the occurrence of hearing loss in patients withdisorders of thyroid function, there are still several unsettled issues, such as theincidence and the severity of hearing impairment, the anatomic site of the auditorypathway involved, and the possible pathogenetic mechanisms. Both congenitalhypothyroidism and environmentally based iodine deficiency are established causes ofhearing loss in humans and rodents. Congenital thyroid deficiency in humans can resultin a profound, hearing deficit, which may be prevented by early hormonal replacementtreatment in infants with hypothyroidism. However, the effect of acute or chronichypothyroidism in adults has not been adequately studied, and most information hasbeen obtained from animal experiments, whereas research in humans has been basicallybased on behavioral audiometry. The use of otoacoustic emissions may provide moreinsight into the hearing function of these patients than pure-tone audiometry, since it isconsidered as a sensitive test of the cochlear status. The aim of this study was toevaluate the hearing in a group of patients with acute hypothyroidism, using bothconventional audiometry and transiently evoked otoacoustic emissions (TEOAEs). Material and methods:A group of 52 patients with thyroid carcinoma who underwent total thyroidectomy wasstudied prospectively, All patients were examined before surgery and 6-8 weekspostoperatively. During this period there was no replacement with levothyroxine and themagnitude of thyroxin depletion was monitored by serum thyroid-stimulating hormone levels. On preoperative encounter with each patient, a detailed questionnaire of historyof hearing loss, tinnitus, vertigo, previous ear infections, noise exposure, medications,and recent upper respiratory tract infection was completed. Patients were excluded ifthey were older than 50 years, in order to avoid the phenomenon of presbycusis, or ifthey had a history of cochleovestibular, vascular or neurologic disease, or any other riskfactor for hearing impairment. Pure-tone audiometry, tympanometry and transientlyevoked otoacoustic emissions were performed. A group of healthy volunteers of similarage and sex were used for comparison.Results:(1) Tympanograms were normal, either on initial testing (75%) or on repeat testing(25%).(2) Audiometry showed elevation of all postoperative hearing thresholds, whereas thethresholds varied significantly across frequency.(3) TEOAE testing showed response signal to noise ratios lower in the postoperativesession (hypothyroid state) than in the preoperative session on all measured frequencies.(4) Emission levels varied significantly across frequency, with maximum responseobserved at 2 kHz.(5) Comparison of significant pure-tone and otoacoustic emission shifts for individualears showed more ears affected in otoacoustic emission testing, indicating subclinicalcochlear involvement.(6) Comparison of hearing thresholds and otoacoustic emission levels between patientsand controls showed significant differences on postoperative testing. Conclusions:Acute hypothyroidism in adults causes elevation of hearing thresholds and reducedotoacoustic emissions. The effect on otoacoustic emissions is greater, indicatingsubclinical damage of the cochlear function.

scholarly journals Universal Neonatal Hearing Screening - a Necessity and not a Choice

2015 ◽  
Vol 23 (1) ◽  
pp. 1-6 ◽  
Author(s):  
Saikat Samaddar ◽  
Swagatam Banerjee ◽  
Sanjoy Kumar Ghosh ◽  
Subhra Bhattacharya ◽  
Diptanshu Mukherjee ◽  
...  
Keyword(s):  
High Risk ◽  
Hearing Impairment ◽  
Risk Group ◽  
High Risk Group ◽  
Hearing Screening ◽  
Congenital Deafness ◽  
Neonatal Hearing Screening ◽  
Universal Neonatal Hearing Screening ◽  
Congenital Hearing Impairment ◽  
Evoked Response Audiometry

INTRODUCTION Congenital deafness in a child is often missed. Several distraction tests have evolved over time to diagnose congenital deafness. These are of limited value in the era of Evoked response audiometry. Evoked responses, such as Oto-acoustic emission (OAE) and Brainstem Evoked Response Audiometry (BERA) have played a significant role in early diagnosis of congenital hearing impairment. The study was conducted to compare the result of neonatal hearing screening in high risk and non high risk neonates.   MATERIALS AND METHODS A study was conducted over a time period of three months at a tertiary care institute to screen all live neonates for congenital hearing impairment using OAE and BERA.   RESULT 1182 neonates were screened for hearing impairment. 336 were in High risk group and rest in Non high risk group. Nine neonates turned out to have abnormal BERA result (absence of wave V). Six of them were high risk babies and rest 3 were non high risk.   DISCUSSION 33.33% of congenital deaf population detected by UNHS belong to the Non High Risk group. Studies across the world suggest at least 50% chance of missing out a congenital deaf child if Universal Neonatal Hearing Screening is not practiced.   CONCLUSION In order to ensure that early detection and effective intervention are made on all newborns with hearing impairment, UNHS should be performed. Three stage UNHS protocol using TEOAEs and BERA showed that the implementation of UNHS for congenital childhood hearing loss among all newborns in India feasible and effective.

scholarly journals Oto acoustic emissions in early detection of sensorineural hearing loss in high-risk neonates

2021 ◽  
Vol 7 (11) ◽  
pp. 1794
Author(s):  
J. Ramanjaneyulu ◽  
S. Rajesh Kumar ◽  
V. Krishna Chaitanya ◽  
A. Kusumanjali
Keyword(s):  
Hearing Loss ◽  
High Risk ◽  
Early Detection ◽  
Sensorineural Hearing Loss ◽  
Brain Stem ◽  
Sensitivity And Specificity ◽  
Acoustic Emissions ◽  
Otoacoustic Emission ◽  
Auditory Neuropathy ◽  
Sensorineural Hearing

<p><strong>Background: </strong>Early identification of congenital hearing loss and early intervention ameliorated many adverse consequences. This study was performed to observe effectiveness of otoacoustic emission in screening of hearing loss in high-risk babies.</p><p><strong>Methods: </strong>Prospective study on 45 high-risk newborns delivered during period of 2013-2014. Selective newborn hearing performed with oto acoustic emissions (OAE) and auditory brain stem responses (ABR), in high-risk infants aged below 7 days, 15 days, after 45 days and after 90 days.</p><p><strong>Results: </strong>Study population comprised of 45 high-risk newborns. In 1<sup>st</sup> level screening, 28 (62%) babies showed recordable OAE, 17 (38%) babies failed. In 2<sup>nd</sup> level screening 31 (81%) passed and 7 (19%) failed and death occurred in 7 infants. In 3<sup>rd</sup> level screening both OAE and brain stem evoked response audiometry (BERA), was performed in 38 cases and positivity was reported in 37 cases. 4<sup>th</sup> level screening was similar to 3<sup>rd</sup> level screening where 3 babies failed ABR test. In our study incidence of sensorineural hearing loss found to be 78.91% (3/38×1000) per 1000 high-risk babies. Auditory neuropathy was observed in 2 (4.4%) patients. Sensitivity and specificity of OAE was 100% and 33.3% respectively. In high-risk low birth weight neonates’ sensitivity and specificity was 66.7% and 50.0%.</p><p><strong>Conclusions: </strong>In high-risk babies, appropriate time for screening with OAE is around 60 days of age. OAE are useful diagnostic tool in evaluation of high-risk neonates for early detection of sensorineural hearing loss.</p>

scholarly journals Newborn hearing screening with transient evoked otoacoustic emission: a prospective study in a tertiary health care centre

2016 ◽  
Author(s):  
Shashidhar S. Suligavi ◽  
Prakhar Upadhyay ◽  
Prasen Reddy ◽  
S. S. Doddamani ◽  
M. N. Patil
Keyword(s):  
Hearing Loss ◽  
Prospective Study ◽  
Hearing Impairment ◽  
Hearing Aids ◽  
Otoacoustic Emissions ◽  
Speech Therapy ◽  
Otoacoustic Emission ◽  
Tertiary Hospital ◽  
Hearing Screening ◽  
Health Care Centre

<p class="abstract"><strong>Background:</strong> As hearing impairment is a hidden disability, it is usually detected after 2-3 years by which time there will be irreversible stunting of the skills and hence rehabilitation procedures like hearing aids, speech therapy are unable to ensure complete development of speech. Therefore hearing impairment should be diagnosed as early as           6 months to ensure timely therapy. The objective of the study is to identify the proportion of incidence of hearing impairment in neonates using transient evoked otoacoustic emissions (TEOAE) as a screening tool.</p><p class="abstract"><strong>Methods:</strong> Prospective study on 800 newborns in a tertiary hospital using TEOAE. Brain stem evoked response audiometry (BERA) was used to confirm hearing loss in neonates who failed TEOAE.  </p><p class="abstract"><strong>Results:</strong> Thirteen out of 800 newborns failed TEOAE test on first screening. Two failed on 2<sup>nd </sup>TEOAE test done after 3-4 weeks. Hearing loss was later confirmed in them with BERA test.</p><strong>Conclusions:</strong> Proportion of hearing loss in our study was 0.25%. Hearing screening should be done as early as possible so that deaf children are rehabilitated early.

scholarly journals Targeted versus Universal Neonatal Hearing Screening in a Single Egyptian Center

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Safaa S. Imam ◽  
Rania A. El-Farrash ◽  
Hesham M. Taha ◽  
Helbees E. Bishoy
Keyword(s):  
Hearing Loss ◽  
Risk Factor ◽  
High Risk ◽  
Otoacoustic Emissions ◽  
Risk Group ◽  
Hearing Screening ◽  
Low Risk ◽  
Brain Response ◽  
Neonatal Hearing Screening ◽  
Universal Neonatal Hearing Screening

Aim. To compare targeted neonatal hearing screening (TNHS) and universal neonatal hearing screening (UNHS) since many developing countries, including Egypt, implement selective screening for high-risk neonates. Methods. 150 neonates were assessed; 50 full terms consecutively admitted to the well-baby nursery and 100 neonates consecutively admitted to neonatal intensive care unit (NICU), Ain Shams University. Patients were further subdivided into high-risk group which included 50 neonates with multiple risk factors for hearing loss and low risk group which included 50 neonates with only one risk factor. Transient evoked otoacoustic emissions (TEOAEs) were used for hearing screening. Auditory brain response (ABR) was performed 3 months later for failed TEOAEs. Results. The most frequent risk factor was consanguinity (46%). In the well-baby population, 16% failed TEOAEs. In the NICU, 30% of the low risk and 38% of the high risk groups failed TEOAEs. Regarding ABR, failed results were 12%, 10%, and 8% in the high-risk, low-risk, and healthy groups, respectively. Conclusion. The use of TNHS would have missed 8% of neonates from the well-baby group who actually had PCHL (permanent congenital hearing loss). The use of UNHS would identify all cases with PCHL, allowing for early intervention and follow-up.

Targeting individuals with new-onset diabetes for early detection of pancreatic cancer in this high risk group

Pancreatology ◽  
2016 ◽  
Vol 16 (3) ◽  
pp. S19
Author(s):  
Lucy Oldfield ◽  
Claire Jenkinson ◽  
Tejpal Purewal ◽  
Robert Sutton ◽  
John P. Neoptolemos ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
High Risk ◽  
Early Detection ◽  
Risk Group ◽  
High Risk Group ◽  
Onset Diabetes ◽  
New Onset

Barrett's Esophagus and Its Progression to Adenocarcinoma

2006 ◽  
Vol 4 (4) ◽  
pp. 367-374 ◽  
Author(s):  
Carlo C. Maley ◽  
Anil K. Rustgi
Keyword(s):  
Clinical Practice ◽  
High Risk ◽  
Early Detection ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Risk Group ◽  
High Risk Group ◽  
Neoplastic Progression ◽  
Inflammatory Drugs ◽  
Gastric Reflux

Barrett's esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EA). Therefore, the presence of BE identifies a high-risk group of patients who may be followed-up for early detection of EA and treated to reduce the risk for its progression. The initiating event for BE is unknown, although it is associated with chronic gastric reflux. Many of the genetic lesions involved in BE neoplastic progression are known, including loss of CDKN2A (p16) and TP53 (p53) and the development of tetraploidy and aneuploidy. Intensive endoscopic surveillance has been shown to improve survival although it can be difficult to implement in practice. Several exposures may be altered to reduce the risk for progression, including weight, diet, and the use of nonsteroidal anti-inflammatory drugs. However, most of these results should be confirmed in additional cohorts before they are used to change clinical practice.

Sign in / Sign up

Export Citation Format

Share Document